These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25876451)

  • 41. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
    Patti F; Visconti A; Capacchione A; Roy S; Trojano M;
    Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K
    Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
    Song Y; Wang Y; Wong SL; Yang D; Sundar M; Tundia N
    Mult Scler Relat Disord; 2023 Nov; 79():105052. PubMed ID: 37832254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M; Grieb P
    Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
    Murphy JA; Harris JA; Crannage AJ
    Neuropsychiatr Dis Treat; 2010 Oct; 6():619-25. PubMed ID: 20957121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
    Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N; Hicking C; Dangond F; Munafo A
    Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.